Zevalin®
Company
Coulter Corporation
Use
Treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Features
The first radioimmunotherapy treatment approved for cancer
NIH Contribution
Method of delivering radioactive compound to the target site while minimizing distribution of the compounds to other organs or tissues
Approval Type
FDA
HHS Institute/Agency
NCI
Inventor(s)
O. Gansow and M. Brechiel
Year
2002
Tech Cat
Biologic
Request More Info
